Drink Thyme Tea Every Morning to Help With Fibromyalgia, Hashimoto’s, Rheumatoid Arthritis, Lupus, and Multiple Sclerosis

Did you know that down through the centuries thyme has been used for many ailments, from influenza to epileptic seizures?  It was often mixed with equal parts of lavender and sprinkled on the floors of churches in the Middle Ages to eliminate any unwanted odors. Long before the discovery of modern medicine, crushed thyme was placed on bandages to promote wound healing and ward off infection.

The volatile essential oils in thyme are loaded with anti-rheumatic, anti-parasiticanti-septic, anti-viral, and anti-fungal properties.

If taken on a regular basis it can significantly help to reduce the viral load in the body which makes it very beneficial in dealing with Chronic Fatigue Syndrome, Fibromyalgia, Hashimoto’s Thyroiditis, Rheumatoid Arthritis, Lupus, Vertigo, Tinnitus, and Multiple Sclerosis.

Thyme is packed with vitamins and minerals. It’s rich in potassium, iron and calcium, all of which contribute to blood pressure regulation, proper red blood cell formation and distribution of antioxidants in the body.  It is rich in high in B-complex vitamins, vitamin A, C and folic acid. Thyme contains a variety of important bioflavonoids and volatile oils, including thymol. Thymol is an essential oil that has very powerful antioxidant properties.

Thyme has cancer preventive properties; containing terpenoids like rosmarinic andursolicacids. (Regular consumption of thyme has been shown to increase the amount of DHA (docosahexaenoic acid, an omega-3 fatty acid) in brain, kidney, and heart cell membranes).

Thyme’s essential oils have expectorant and bronchial antispasmodic properties treating…

  • acute and chronic bronchitis
  • sore throats
  • coughs
  • laryngitis
  • asthma
  • treats inflammation of the mouth
  • throat infections
  • prevent gingivitis

Drink Thyme Tea Every Morning to Help Cure Fibromyalgia, Hashimoto’s, Rheumatoid Arthritis, Lupus, and Multiple Sclerosis.

How to Make Thyme Tea

Ingredients:

  • Thyme (dried or a handful of fresh)
  • A covered container for brewing & straining
  • Mug

How to make Thyme Tea, Instructions.

1) Put some herbs in your brewing container – about 1 tsp dried herbs per cup of water.  For fresh herbs, use more.

2) Pour over water that’s just off the boil.

3) Cover and infuse for about 5 minutes.

4) Strain and serve.

 

Source:healthnutnews.com

Gabapentin-caution-2

6 Facts You Should Know About Gabapentin

There are roughly 30 million prescriptions written each year in the United States for the drug gabapentin to treat various chronic pain conditions. Patients sometimes shy away from asking their doctor and pharmacist about the drugs that are prescribed to them, so here are 6 quick facts about gabapentin that are useful for facilitating a discussion between you and your healthcare provider.

  1. Gabapentin, sometimes know by its brand name Neurontin, was invented to treat seizures.
  2. Gabapentin has also been approved by the FDA to treat post herpetic neuralgia, better known as nerve pain after shingles and restless leg syndrome.
  3. Gabapentin is often prescribed to treat several conditions that it has not been approved for, such diabetic neuropathy, fibromyalgia, chronic headaches,  and mood disorders, although data suggests it may not be that effective for these conditions.
  4. The main side effect for gabapentin is feeling sleepy, and many people have a tough time functioning when taking it.  Some people can’t drive when taking gabapentin and you should not operate heavy machinery while taking this medication.
  5. Weight gain can be a significant issue for some patients taking gabapentin, although the issue is not as severe as with the second generation of the drug, Lyrica.
  6. You have to be careful when stopping taking gabapentin, because it is intended to treat seizures, theoretically stopping this medication abruptly may cause seizures in people who have never had them before.

Talk to your healthcare provider about gabapentin to make sure it is the right drug for your condition and lifestyle. Always ask your doctor about prescription and non-prescription alternatives to drugs that you don’t feel comfortable taking, and always inform your doctor of any vitamins, herbs and dietary supplements that you are taking prior to starting a new drug therapy.

 

Source:tmedhealth

Fibromyalgia : CBT/Exercise Training May Get Teens Moving

Routine physical exercise is an important factor in managing widespread musculoskeletal pain in conditions such as fibromyalgia (FM), but patients may fear that such exertion will worsen pain. Now, results of a pilot study suggest that a combination of cognitive behavioral therapy (CBT) that emphasizes pain coping strategies and a specially tailored exercise program reduces this fear for teenagers with juvenile fibromyalgia (JFM). The program also improved physical function and may help these patients become more physically active.

Susan T. Tran, PhD, from the Department of Psychology, DePaul University, Chicago, Illinois, and colleagues reported preliminary outcomes for 22 patients in an article published online June 22 in Arthritis Care & Research.

“Results of this pilot study indicated that adolescents with JFM reported significant improvements in physical function and reduced fear of movement following the intervention,” the authors write. “Improvement in physical function was achieved in a shorter time frame than a prior trial of CBT without an exercise component.” They plan further to determine whether these outcomes result in changes in exercise participation and whether combined CBT/exercise is better than existing approaches.

The 8-week, 16-session intervention developed by Dr Tran and colleagues, dubbed the Fibromyalgia Integrative Training for Teens (FIT Teens) program, included twice-weekly 90-minute small-group treatment sessions. Sessions were led jointly by a psychology postdoctoral fellow or pediatric pain psychologist and an exercise physiologist or physical therapist. Parents were included in 6 of the 8 weeks. There was no control group.

Each session included approximately 45 minutes of CBT training in behavioral pain management techniques and 45 minutes of neuromuscular exercises to improve strength, fitness, and body mechanics. CBT included education about the gate-control theory of pain, as well as coping skills such as distraction, relaxation techniques, activity pacing, problem solving, and changing negative and catastrophic thoughts about pain. These skills were then practiced with coaching from the psychology fellow or psychologist while the participants went through the exercise training.

Exercise training used only bodyweight resistance exercises to permit easy home use of the program. Subjects progressed through four increasingly strenuous levels of resistance training during the 8 weeks.

“Education normalizing temporary muscle soreness when beginning a new exercise regimen and differentiating muscle soreness from a JFM pain flare was also discussed, as well as the applicability of each of the exercises for improved performance of activities of daily living—e.g., walking, lifting, and climbing stairs,” the authors write.

Progress was monitored via daily diaries that included ratings of daily pain intensity, sleep, fatigue, practice of coping skills, and physical exercise. Patients also completed self-report measures of pain, functional disability, depressive symptoms, and fear of movement. The following tools were used for symptom assessment: a 10-point visual analogue scale for pain intensity, the functional Disability Inventory, the Children’s Depression Inventory, the Tampa Scale for Kinesophobia, the Pain Catastrophizing Scale for Children, and the Pain Stages of Change Questionnaire to assess readiness to self-manage pain.

The researchers enrolled 22 female patients (aged 12 – 18 years) from two urban children’s hospitals. Patients were treated in groups of two to four. Eligibility criteria included JFM diagnosis by a pediatric rheumatologist or pain physician, using Yunus and Masi criteria (widespread pain, at least five tender points, and associated symptoms such as fatigue or sleep disturbance). Eligibility also required an average visual analogue scale pain intensity of more than 4 and a Functional Disability Score of more than 7 (at least mild disability). Exclusion criteria included severe depression, comorbid rheumatic disease, other untreated major psychiatric diagnosis, or developmental delay.

The researchers report that comparison of pre- vs postintervention assessments showed significant decreases in functional disability, depression fear of movement, and pain catastrophizing, as well as significant improvements in “readiness to change” measures.

There was no significant effect on pain intensity, although pain scores decreased. The researchers suggest that the gradual increases in physical activity during this 8-week program might not have been sufficient to attain the kind of pain reduction seen after longer aerobic exercise studies.

“This multi-site investigation provides promising initial evidence for the feasibility and efficacy of a novel intervention that combines CBT with neuromuscular training to reduce disability and fear of movement, while improving psychological coping and readiness to engage in self-management for pain. As we have reported in a previously published qualitative study, once enrolled, patients find FIT Teens highly engaging, report no adverse effects other than temporary muscle soreness, and greatly enjoy the group-format of this program,” the authors write.

They also note that physical function improvements were achieved faster than in a prior trial of traditional pain-focused CBT without exercise.

Study limitations included lack of a control group, which precludes ruling out a placebo effect, and lack of objective measures such as physical activity and biomechanical outcomes.

The study was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The authors have disclosed no relevant financial relationships.

 

Source:medscape

Fibromyalgia, Chronic Pain Two-Year Study Published

A two-year study of fibromyalgia and chronic pain by an international team of investigators, concluded that fibromyalgia (FM) patients experience symptom ebbs and flows that effect diagnosis and treatment.

The study, “Progression of fibromyalgia: results from a 2-year observational fibromyalgia and chronic pain study in the US,“  published online by the Journal of Pain Research aimed to provide a better understanding of fibromyalgia’s progression over a two-year [eriod, based on findings from a previous study that indicated 20 percent to 47 percent of  FM patients no longer met the definition of the chronic disease two years after diagnosis.

The current study followed 226 patients who met strict criteria for participation.  They completed an online questionnaire consisting of the London Fibromyalgia Epidemiology Study Screening Questionnaire used to check for CWP (bilateral pain above/below waist lasting at least one week during the preceding three months), visited a site for physician evaluation for FM, and completed a questionnaire containing validated patient-reported outcome questions.

Subjects were then categorized into three groups: those who screened positive for CWP and received physician diagnosis of FM (FM+CWP+); those who screened positive for CWP but did not receive physician diagnosis of FM (FM-CWP+); and those with FM who screened negative for CWP (FM-CWP-).

In follow-up approximately two years later, subjects were reassessed at the same study site and completed a questionnaire with the same questions.

Of the 76 FM+CWP+ subjects, 56 (73.7 percent) still met the FM study diagnostic definition at the time of follow-up, while 20 subjects no longer met the FM study definition (of which eleven became FM-CWP- and nine became FM-CWP+).

Ten subjects (two from FM-CWP- and eight from FM-CWP+) transitioned into the FM+CWP+ group at follow-up, reporting more tender points and pain interference with sleep, and generally worse physical function at baseline compared with subjects who did not transition to FM+CWP+.

Most (76.7 percent) of the subjects who transitioned into, or out of, FM+CWP+ experienced changes in CWP, the number of positive tender points, or both.

Based on the findings, the investigators suggest that some FM+CWP+ patients experience fluctuations in symptom intensity and severity over time, which may reflect a “waxing and waning nature” of FM, and effects diagnosis and treatment of the disorder.

The paper coauthors observed that the results of the study support previous research suggesting that while FM is a chronic illness there is fluation of symtoms, with some improvement following diagnosis and care. But they also emphasized that the majority of FM+CWP+ patients at baseline were also CWP+ patients and were rediagnosed by the physician at follow-up. The facts pointed toward the concensus that FM patients in the study were generally stable over the two-year study period.

Also, at the follow-up assessment, ten subjects who had not met diagnostic criteria for FM at baseline now met the study definition of FM. Data from the ten individuals suggested that a high number of FM tender points and modified ACR 2010 criteria scores, and suboptimal physical function and pain interference with sleep outcomes may be present in patients who develop FM.

The findings concur with previous research that found the number of painful regions among individuals presenting with no chronic pain and chronic regional pain at baseline was the strongest predictor of CWP development at the time of a 3-year follow-up.

The researchers noted that results of both previously published studies and the current findings suggest that some FM patients may experience short or long-term remission of FM symptoms, and that the concept of FM being part of a larger continuum of central pain disorders, identified as central sensitivity syndromes, may play a role in symptom variation.

Among patients in the study who no longer met the FM at follow-up, only one had stopped taking a medication class, with the majority of changes in medication use between the baseline and follow-up assessments being initiation of new medication classes, which they say could suggest that initiation of new medications may have contributed to symptom relief resulting in some of the subjects no longer meeting study criteria for FM diagnosis.

Accordingly, proactive management (both pharmacologic and nonpharmacologic) in the initial years following FM diagnosis could influence long-term outcomes in some FM patients, although the researchers caution that the findings are preliminary and additional research on this topic and on predictors of CWP and FM in general is needed.

Source:fibromyalgianews